{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-101292","form_type":"8-K","ticker":null,"cik":"0001466301","company_name":"Clovis Oncology, Inc.","filed_at":"2023-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.948130+00:00","generated_at":"2026-06-17T01:54:11.430339+00:00","sec_items":["2.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Clovis Oncology completes sale of FAP-2286 to Novartis amid Chapter 11","bullets":["Sale of pipeline targeted radionuclide therapy program FAP-2286 closed April 14, 2023.","Court approved the transaction on March 21, 2023; sale includes in-licensing agreement with 3B Pharmaceuticals.","Company expects no payment to common stockholders given senior debt and contingent milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-101292","json":"https://secwatch.observer/filing/0001193125-23-101292.json","markdown":"https://secwatch.observer/filing/0001193125-23-101292.md","text":"https://secwatch.observer/filing/0001193125-23-101292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1466301/000119312523101292/0001193125-23-101292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1466301/000119312523101292/d458873d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:54:11.430339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e25ac1661edce2a7a2269a2bd804d6425c9c918","claim":"Clovis Oncology, Inc. completed a disposition involving Novartis Innovative Therapies AG (closed 2023-04-14).","evidence_excerpt":"On April 14, 2023, the Company and Novartis consummated the FAP Sale Transaction.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1466301/000119312523101292/0001193125-23-101292-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Novartis Innovative Therapies AG"},{"label":"Closing","value":"2023-04-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}